



Final Appraisal Recommendation

Advice No: 0412 – February 2012

Capsaicin 8% patch (Qutenza®)

Submission by Astellas Pharma Ltd

Recommendation of AWMSG

Capsaicin patch (Qutenza®) is not recommended for use alone for the treatment of peripheral neuropathic pain (PNP) in non-diabetic adults.

Capsaicin patch (Qutenza®) is recommended as an option for restricted use within NHS Wales for the treatment of peripheral neuropathic pain (PNP) in non-diabetic adults in combination with other medicinal products for pain and in patients who have not received adequate benefit from, or are intolerant to, alternative conventional treatments.

The company submission provided evidence on the cost effectiveness of capsaicin patch (Qutenza®) as an add-on treatment in patients who were refractory to or intolerant of usual first or second line treatments.

Capsaicin patches (Qutenza®) should be administered by healthcare professionals who have completed the approved training and in a specialist clinic setting.

AWMSG is of the opinion that capsaicin patch (Qutenza®) is suitable for specialist only prescribing within NHS Wales for the above indication.

In reaching this recommendation AWMSG took account of the AWMSG Secretariat Assessment Report (ASAR), the preliminary appraisal recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), lay/patient/carer perspective (where available) and discussions at AWMSG.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue:	Astellas Pharma Ltd
Date of first issue	February 2012
Last reviewed	September 2016



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at www.evidence.nhs.uk.

For full details on our accreditation visit: www.nice.org.uk/accreditation.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 0412: Capsaicin patch (Qutenza®). February 2012.

